Splenectomy before hepatectomy for patients with hepatocellular carcinoma and hypersplenism: A retrospective study

Medicine (Baltimore). 2021 Jan 29;100(4):e24326. doi: 10.1097/MD.0000000000024326.

Abstract

The spleen plays an important role in tumor progression and the curative effects of splenectomy before hepatectomy for hypersplenism and hepatocellular carcinoma (HCC) are not clear. We investigated whether splenectomy before hepatectomy increases survival rate among patients with HCC and hypersplenism compared with that of patients who underwent synchronous hepatectomy and splenectomy or hepatectomy alone.Between January 2011 and December 2016, 266 patients who underwent hepatectomy as a result of HCC and portal hypertension secondary to hepatitis were retrospectively analyzed. Their perioperative complications and survival outcome were evaluated.Patients underwent synchronous hepatectomy and splenectomy (H-S group) and underwent splenectomy before hepatectomy (H-preS group) exhibited significantly higher disease-free survival (DFS) rates than those of patients underwent hepatectomy alone (H-O group). The DFS rates for patients in the H-S group, H-preS group, and H-O group were 74.6%, 48.4%, 39.8%, and 80.1%, 54.2%, 40.1%, and 60.5%, 30.3%, 13.3%, at 1, 3, and 5 years after surgery, respectively. Tumor size, tumors number, and levels of alpha fetoprotein (AFP) were independent risk factors for DFS. Gender and tumor size were independent prognostic factor for overall survival (OS). The preoperative white blood cell (WBC) and platelet (PLT) counts were significantly higher in the H-preS group than in those of the H-S group and the H-O group. After operation, the WBC and PLT counts in the H-S group and H-preS groups were significantly higher compared to those of the H-O group.No matter splenectomy before hepatectomy or synchronous hepatectomy and splenectomy, hepatectomy with splenectomy may improve DFS rates in patients with HCC and hypersplenism, and splenectomy before hepatectomy alleviates hypersplenism without an increased surgical risk.

Publication types

  • Evaluation Study

MeSH terms

  • Adult
  • Biomarkers / blood
  • Carcinoma, Hepatocellular / complications
  • Carcinoma, Hepatocellular / mortality
  • Carcinoma, Hepatocellular / surgery*
  • Combined Modality Therapy
  • Disease-Free Survival
  • Female
  • Hepatectomy / methods
  • Hepatectomy / mortality*
  • Humans
  • Hypersplenism / complications
  • Hypersplenism / mortality
  • Hypersplenism / surgery*
  • Leukocyte Count
  • Liver Neoplasms / complications
  • Liver Neoplasms / mortality
  • Liver Neoplasms / surgery*
  • Male
  • Middle Aged
  • Platelet Count
  • Prognosis
  • Retrospective Studies
  • Splenectomy / methods
  • Splenectomy / mortality*
  • Survival Rate
  • Time Factors
  • Treatment Outcome
  • alpha-Fetoproteins / analysis

Substances

  • AFP protein, human
  • Biomarkers
  • alpha-Fetoproteins